Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2022 Filed Jul 6, 2022 01:34 UTC |
Salkind GeneDirector · 10% owner
|
ConversionCommon Stock | 408,000 | $1.25 | $510,000.00 |
DisclosureSEC source: 0001683168-22-004784 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,992,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The 2,992,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust. Read SEC document |
| April 01, 2022 Filed Mar 24, 2023 19:56 UTC |
Julia Dean L.Director · Chief Executive Officer
|
GrantCommon Stock Options · Derivative | 12,500 | Not disclosed Strike: $60.00 | Not disclosed |
DisclosureSEC source: 0001683168-23-001747 · ownership.xml · derivative · entry 1 Julia Dean L. · CIK 0001317363 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 12,500 shares Expires 2032-04-01 F1 · price: Not applicable Read SEC document |
| March 30, 2022 Filed Mar 31, 2022 23:51 UTC |
Salkind GeneDirector · 10% owner
|
ConversionWarrants · Derivative | 684,166 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001683168-22-002246 · ownership.xml · derivative · entry 3 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,237,500 Underlying: CommonStock · 684,166 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The 2,484,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust. F2 · security: After the close of business on March 29, 2022 and prior to the close of the market on March 30, 2022, the board of directors of the issuer accepted Dr. Salkind's offer to convert $2,052,500 of convertible notes at a reduced conversion price of $1.50 per share into 1,368,333 common shares and warrants to purchase 684,166 shares at an exercise price of $4.00 per share through September 30, 2029. A portion (i.e. $1,542,500) of the note conversion came directly from Dr. Salkind and his wife and a portion (i.e.$510,000) of the note conversion came directly from the trust that Dr. Salkind is the trustee. F3 · price: Not applicable. F5 · balance_after: 1,237,500 derivative securities include the following: (i) 127,500 shares underlying $510,000 of debt, convertible at $4.00 per share (excluding 50% warrant coverage - i.e. 63,750 warrants, exercisable at $4.00 per share through September 30, 2029, if and when issued); (ii) 390,625 common stock purchase warrants exercisable at $4.00 per share through September 2023; (iii) 10-year options to purchase 35,000 shares granted on December 8, 2021; and (iv) warrants to purchase 686,166 shares exercisable through September 30, 2029 which were issuable on March 30, 2022 as a result of the note conversion. Read SEC document |
| March 30, 2022 Filed Mar 31, 2022 23:51 UTC |
Salkind GeneDirector · 10% owner
|
ConversionNotes · Derivative | Not disclosed | Not disclosed Strike: $1.50 | $2,052,500.00 |
DisclosureSEC source: 0001683168-22-002246 · ownership.xml · derivative · entry 2 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,500 Underlying: Common Stock · 513,125 shares Expires 2029-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The 2,484,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust. F2 · security: After the close of business on March 29, 2022 and prior to the close of the market on March 30, 2022, the board of directors of the issuer accepted Dr. Salkind's offer to convert $2,052,500 of convertible notes at a reduced conversion price of $1.50 per share into 1,368,333 common shares and warrants to purchase 684,166 shares at an exercise price of $4.00 per share through September 30, 2029. A portion (i.e. $1,542,500) of the note conversion came directly from Dr. Salkind and his wife and a portion (i.e.$510,000) of the note conversion came directly from the trust that Dr. Salkind is the trustee. F3 · price: Not applicable. F4 · balance_after: The remaining unpaid convertible notes in the principal amount of $510,000 are convertible into 127,500 shares at $4.00 per share, excluding 63,750 warrants issuable upon conversion thereof as described in note 5. Read SEC document |
| March 30, 2022 Filed Mar 31, 2022 23:51 UTC |
Salkind GeneDirector · 10% owner
|
ConversionCommon Stock | 1,368,333 | $1.50 | $2,052,499.50 |
DisclosureSEC source: 0001683168-22-002246 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,484,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The 2,484,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust. Read SEC document |
| March 18, 2022 Filed Mar 23, 2022 16:49 UTC |
Provost Anne SchmidtDirector
|
GrantCommon Stock Options · Derivative | 25,000 | Not disclosed Strike: $4.57 | Not disclosed |
DisclosureSEC source: 0001683168-22-001868 · ownership.xml · derivative · entry 1 Provost Anne Schmidt · CIK 0001919163 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-12-08 F1 · price: Not applicable. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 02:59 UTC |
BARRETT DON WALKER IIIDirector · Chief Oper. & Strategy Officer
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001683168-22-000109 · ownership.xml · derivative · entry 2 BARRETT DON WALKER III · CIK 0001570410 · Director · Chief Oper. & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2026-12-31 F2 · derivative.exercise_date: In accordance with the terms of the Issuer's 2021 Employee Benefit and Consulting Services Compensation Plan, the options shall vest in three substantially equal annual installments of 50,000 shares on each of (i) January 1, 2023, (ii) January 1, 2024, and (iii) January 1, 2025, provided the Reporting Person remains employed by the Issuer on such dates. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 02:59 UTC |
BARRETT DON WALKER IIIDirector · Chief Oper. & Strategy Officer
|
GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-22-000109 · ownership.xml · nonDerivative · entry 1 BARRETT DON WALKER III · CIK 0001570410 · Director · Chief Oper. & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: The Reporting Person was granted Restricted Stock which, in accordance with the terms of a Restricted Stock Grant Agreement, shall vest in full on July 1, 2022, provided the Reporting Person is employed by the Issuer on such date. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:07 UTC |
Trepeta SeanPres of Mobiquity Networks
|
GrantCommon Stock Options · Derivative | 125,000 | Not disclosed Strike: $4.57 | Not disclosed |
DisclosureSEC source: 0001683168-21-006266 · ownership.xml · derivative · entry 1 Trepeta Sean · CIK 0001538450 · Pres of Mobiquity Networks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,750 Underlying: Common Stock · 125,000 shares Expires 2031-12-08 F1 · price: Not applicable. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:00 UTC |
Julia Dean L.Director · CEO
|
GrantCommon Stock Options · Derivative | 250,000 | Not disclosed Strike: $4.57 | Not disclosed |
DisclosureSEC source: 0001683168-21-006261 · ownership.xml · derivative · entry 1 Julia Dean L. · CIK 0001317363 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,500 Underlying: Common Stock · 250,000 shares Expires 2031-12-08 F1 · price: Not applicable. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:00 UTC | GrantCommon Stock Options · Derivative | 25,000 | Not disclosed Strike: $4.57 | Not disclosed |
DisclosureSEC source: 0001683168-21-006260 · ownership.xml · derivative · entry 1 McDonnell Sean · CIK 0001318020 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 25,000 shares Expires 2031-12-08 F1 · price: Not applicable. Read SEC document |
|
| December 08, 2021 Filed Dec 10, 2021 21:00 UTC |
Iacovone AnthonyDirector
|
GrantCommon Stock Options · Derivative | 25,000 | Not disclosed Strike: $4.57 | Not disclosed |
DisclosureSEC source: 0001683168-21-006259 · ownership.xml · derivative · entry 1 Iacovone Anthony · CIK 0001766713 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-12-08 F1 · price: Not applicable. F2 · balance_after: Does not include common stock purchase warrants to purchase 3,906 shares of common stock at an exercise price of $48 per share held indirectly through AJI Capital LLC. The reporting person is the sole member of AJI Capital LLC. As such, the reporting person may be deemed to have sole voting and investment power over the warrants owned by AJI Capital LLC. The reporting person disclaims beneficial ownership of such warrants, except to the extent other reporting persons pecuniary interest. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:00 UTC |
Zurkow Peter L.Director
|
GrantCommon Stock Options · Derivative | 25,000 | Not disclosed Strike: $4.57 | Not disclosed |
DisclosureSEC source: 0001683168-21-006263 · ownership.xml · derivative · entry 1 Zurkow Peter L. · CIK 0001897754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-12-08 F1 · price: Not applicable. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:00 UTC |
Wright Michael A.Director
|
GrantCommon Stock Options · Derivative | 25,000 | Not disclosed Strike: $4.57 | Not disclosed |
DisclosureSEC source: 0001683168-21-006262 · ownership.xml · derivative · entry 1 Wright Michael A. · CIK 0001641690 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-12-08 F1 · price: Not applicable. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:00 UTC |
Bauersfeld PaulChief Technology Officer
|
GrantCommon Stock Options · Derivative | 125,000 | Not disclosed Strike: $4.57 | Not disclosed |
DisclosureSEC source: 0001683168-21-006264 · ownership.xml · derivative · entry 1 Bauersfeld Paul · CIK 0001629264 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,500 Underlying: Common Stock · 125,000 shares Expires 2031-12-08 F1 · price: Not applicable. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:00 UTC |
Salkind GeneDirector · 10% owner
|
GrantCommon Stock Options · Derivative | 35,000 | Not disclosed Strike: $4.57 | Not disclosed |
DisclosureSEC source: 0001683168-21-006258 · ownership.xml · derivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,422,500 Underlying: Common Stock · 35,000 shares Expires 2031-12-08 F1 · price: Not applicable. F2 · balance_after: 1,422,500 derivative securities include the following: (i) 675,000 shares underlying $2.7 million of debt, convertible at $4.00 per share with 50% warrant coverage (i.e. 337,500 warrants, exercisable at $4.00 per share through September 30, 2029, if and when issued); (ii) 375,000 common stock purchase warrants exercisable at $48 per share through September 20, 2023; and (iii) options to purchase 35,000 shares granted on December 8, 2021, which options necessitated this filing. Read SEC document |
| December 08, 2021 Filed Mar 24, 2023 19:55 UTC Amendment |
Julia Dean L.Director · CEO
|
GrantCommon Stock Options · Derivative | 250,000 | Not disclosed Strike: $4.57 | Not disclosed |
DisclosureSEC source: 0001683168-23-001744 · ownership.xml · derivative · entry 1 Julia Dean L. · CIK 0001317363 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,500 Underlying: Common Stock · 250,000 shares Expires 2031-12-08 F1 · price: Not applicable Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 23:30 UTC |
Salkind GeneDirector · 10% owner
|
Exercise / conversionCommon Stock Purchase Warrants · Derivative | 375,000 | Not disclosed Strike: $48.00 | Not disclosed |
DisclosureSEC source: 0001683168-21-004684 · ownership.xml · derivative · entry 3 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,387,500 Underlying: Common Stock · 375,000 shares Expires 2023-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Includes securities or derivative securities heldboth jointly with his spouse and in trust. F5 · price: None. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 23:30 UTC |
Salkind GeneDirector · 10% owner
|
Exercise / conversionPreferred Stock · Derivative | 1,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-21-004684 · ownership.xml · derivative · entry 2 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012,500 Underlying: Common stock · 750,000 shares Expires 2021-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Includes securities or derivative securities heldboth jointly with his spouse and in trust. F1 · derivative.exercise_price: Not applicable - reporting person converted oneshare of Series C preferred stock into 250 common shares and 250 warrants,exercisable at $48 per share. F3 · shares: Represents 1,500 shares of Series C preferredstock converted into 375,000 shares of common stock and a like number ofwarrants, exercisable at $48 per share through September 20, 2023. F5 · price: None. F4 · derivative.underlying_shares: Includes 375,000 common shares and 375,000warrants, exercisable at $48 per share through September 20, 2023. F6 · balance_after: Includes 675,000 shares underlying $2.7million of debt convertible at $4 per share, with 50% warrant coverage (i.e. 337,500 warrants). The warrants are exercisable at $4per share through September 30, 2029, if and when, issued.The foregoing numbers exclude interest payable on the debt, which can also beconverted on the same basis. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 23:30 UTC |
Salkind GeneDirector · 10% owner
|
Exercise / conversionCommon Stock | 375,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-21-004684 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,116,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Includes securities or derivative securities heldboth jointly with his spouse and in trust. F1 · price: Not applicable - reporting person converted oneshare of Series C preferred stock into 250 common shares and 250 warrants,exercisable at $48 per share. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 21:21 UTC |
Salkind GeneDirector · 10% owner
|
GrantNotes · Derivative | 150,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001683168-21-001191 · ownership.xml · derivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,684,375 Underlying: Common Stock · 56,250 shares Expires 2029-09-30 F1 · security: Includes securities held directly and in family Trusts. F2 · price: Not applicable. Read SEC document |
| April 01, 2021 Filed Mar 24, 2023 19:56 UTC |
Julia Dean L.Director · Chief Executive Officer
|
GrantCommon Stock Options · Derivative | 12,500 | Not disclosed Strike: $60.00 | Not disclosed |
DisclosureSEC source: 0001683168-23-001746 · ownership.xml · derivative · entry 1 Julia Dean L. · CIK 0001317363 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 12,500 shares Expires 2031-04-01 F1 · price: Not applicable Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 18:22 UTC |
Salkind GeneDirector · 10% owner
|
GrantCommon Stock | 15,000,000 | $0.01 | $150,000.00 |
DisclosureSEC source: 0001683168-20-003070 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,318,355 F1 · security: Excludes Preferred Stock Convertible into 150 Million Common Shares and Warrants to purchase an additional 150 million Common Shares. F2 · security: Includes securities held directly and in family Trusts. Read SEC document |
| July 21, 2020 Filed Aug 4, 2020 18:39 UTC |
Salkind GeneDirector · 10% owner
|
GrantCommon Stock | 15,000,000 | $0.01 | $150,000.00 |
DisclosureSEC source: 0001683168-20-002489 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,318,355 F1 · security: Excludes Preferred Stock Convertible into 150 Million Common Shares and Warrants to purchase an additional 150 million Common Shares. F2 · security: Includes securities held directly and in family Trusts. Read SEC document |
| April 01, 2020 Filed Mar 24, 2023 19:55 UTC |
Julia Dean L.Director · Chief Executive Officer
|
GrantCommon Stock Options · Derivative | 12,500 | Not disclosed Strike: $60.00 | Not disclosed |
DisclosureSEC source: 0001683168-23-001745 · ownership.xml · derivative · entry 1 Julia Dean L. · CIK 0001317363 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 12,500 shares Expires 2030-04-01 F1 · price: Not applicable Read SEC document |
| September 13, 2019 Filed Sep 19, 2019 17:49 UTC |
Salkind GeneDirector · 10% owner
|
GrantNotes · Derivative | 2,300,000 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0001683168-19-002976 · ownership.xml · derivative · entry 4 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,502,500 Underlying: Common Stock · 28,750,000 shares Expires 2029-09-13 F2 · price: Not applicable. F4 · balance_after: Excludes 14,375,000 warrants issuable upon Note Conversion. Read SEC document |
| September 13, 2019 Filed Sep 19, 2019 17:49 UTC |
Salkind GeneDirector · 10% owner
|
PurchaseCommon Stock | 12,500,000 | $0.04 | $500,000.00 |
DisclosureSEC source: 0001683168-19-002976 · ownership.xml · nonDerivative · entry 3 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,318,355 F1 · security: Excludes Preferred Stock Convertible into 150 Million Common Shares and Warrants to purchase an additional 150 million Common Shares. F3 · security: Includes securities held directly and in family Trusts. Read SEC document |
| September 13, 2019 Filed Sep 19, 2019 17:49 UTC |
Salkind GeneDirector · 10% owner
|
PurchaseCommon Stock | 127,500,000 | $0.02 | $2,358,750.00 |
DisclosureSEC source: 0001683168-19-002976 · ownership.xml · nonDerivative · entry 2 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,818,355 F1 · security: Excludes Preferred Stock Convertible into 150 Million Common Shares and Warrants to purchase an additional 150 million Common Shares. F3 · security: Includes securities held directly and in family Trusts. Read SEC document |
| September 13, 2019 Filed Sep 19, 2019 17:49 UTC |
Salkind GeneDirector · 10% owner
|
PurchaseCommon Stock | 35,000,000 | $0.01 | $336,000.00 |
DisclosureSEC source: 0001683168-19-002976 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,318,355 F1 · security: Excludes Preferred Stock Convertible into 150 Million Common Shares and Warrants to purchase an additional 150 million Common Shares. F3 · security: Includes securities held directly and in family Trusts. Read SEC document |
| September 13, 2019 Filed Jan 21, 2020 18:18 UTC Amendment |
Salkind GeneDirector · 10% owner
|
GrantNotes · Derivative | 2,300,000 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0001683168-20-000197 · ownership.xml · derivative · entry 4 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,502,500 Underlying: Common Stock · 28,750,000 shares Expires 2029-09-30 F2 · price: Not applicable. F4 · balance_after: Excludes 14,375,000 warrants issuable upon Note Conversion. Read SEC document |
| September 13, 2019 Filed Jan 21, 2020 18:18 UTC Amendment |
Salkind GeneDirector · 10% owner
|
PurchaseCommon Stock | 12,500,000 | $0.04 | $500,000.00 |
DisclosureSEC source: 0001683168-20-000197 · ownership.xml · nonDerivative · entry 3 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,318,355 F1 · security: Excludes Preferred Stock Convertible into 150 Million Common Shares and Warrants to purchase an additional 150 million Common Shares. F3 · security: Includes securities held directly and in family Trusts. Read SEC document |
| September 13, 2019 Filed Jan 21, 2020 18:18 UTC Amendment |
Salkind GeneDirector · 10% owner
|
PurchaseCommon Stock | 127,500,000 | $0.02 | $2,358,750.00 |
DisclosureSEC source: 0001683168-20-000197 · ownership.xml · nonDerivative · entry 2 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,818,355 F1 · security: Excludes Preferred Stock Convertible into 150 Million Common Shares and Warrants to purchase an additional 150 million Common Shares. F3 · security: Includes securities held directly and in family Trusts. Read SEC document |
| September 13, 2019 Filed Jan 21, 2020 18:18 UTC Amendment |
Salkind GeneDirector · 10% owner
|
PurchaseCommon Stock | 35,000,000 | $0.01 | $336,000.00 |
DisclosureSEC source: 0001683168-20-000197 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,318,355 F1 · security: Excludes Preferred Stock Convertible into 150 Million Common Shares and Warrants to purchase an additional 150 million Common Shares. F3 · security: Includes securities held directly and in family Trusts. Read SEC document |
| July 19, 2019 Filed Jul 29, 2019 12:35 UTC |
Salkind GeneDirector · 10% owner
|
GrantWarrants · Derivative | 1,562,500 | Not disclosed Strike: $0.12 | Not disclosed |
DisclosureSEC source: 0001683168-19-002366 · ownership.xml · derivative · entry 2 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,812,500 Underlying: Common Stock · 1,562,500 shares Expires 2023-09-30 F2 · price: Not applicable. Read SEC document |
| July 19, 2019 Filed Jul 29, 2019 12:35 UTC |
Salkind GeneDirector · 10% owner
|
GrantCommon Stock | 3,125,000 | $0.08 | $250,000.00 |
DisclosureSEC source: 0001683168-19-002366 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,318,355 F1 · balance_after: Excludes Preferred Stock Convertible into 150 Million Common Shares and Warrants to purchase an additional 150 million Common Shares. Read SEC document |
| July 14, 2019 Filed Jul 29, 2019 12:32 UTC |
Salkind GeneDirector · 10% owner
|
GrantCommon Stock | 12,500,000 | $0.04 | $500,000.00 |
DisclosureSEC source: 0001683168-19-002365 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,193,355 F1 · balance_after: Excludes Preferred Stock Convertible into 150 Million Common Shares and Warrants to purchase an additional 150 million Common Shares. Read SEC document |
| June 18, 2019 Filed Jul 29, 2019 12:30 UTC |
Salkind GeneDirector · 10% owner
|
GrantWarrants · Derivative | 1,562,500 | Not disclosed Strike: $0.12 | Not disclosed |
DisclosureSEC source: 0001683168-19-002364 · ownership.xml · derivative · entry 2 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,250,000 Underlying: Common Stock · 1,562,500 shares Expires 2023-09-30 F2 · price: Not applicable. Read SEC document |
| June 18, 2019 Filed Jul 29, 2019 12:30 UTC |
Salkind GeneDirector · 10% owner
|
GrantCommon Stock | 3,125,000 | $0.08 | $250,000.00 |
DisclosureSEC source: 0001683168-19-002364 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,693,355 F1 · balance_after: Excludes Preferred Stock Convertible into 150 Million Common Shares and Warrants to purchase an additional 150 million Common Shares. Read SEC document |
| May 03, 2019 Filed May 22, 2019 18:52 UTC |
Salkind GeneDirector · 10% owner
|
GrantWarrants · Derivative | 3,437,500 | Not disclosed Strike: $0.12 | Not disclosed |
DisclosureSEC source: 0001683168-19-001688 · ownership.xml · derivative · entry 2 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,687,500 Underlying: Common Stock · 3,437,500 shares Expires 2023-09-30 F2 · price: Not applicable. Read SEC document |
| May 03, 2019 Filed May 22, 2019 18:52 UTC |
Salkind GeneDirector · 10% owner
|
GrantCommon Stock | 6,875,000 | $0.08 | $550,000.00 |
DisclosureSEC source: 0001683168-19-001688 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,658,355 F1 · balance_after: Excludes Preferred Stock Convertible into 150 Million Common Shares and Warrants to purchase an additional 150 million Common Shares. Read SEC document |
| May 03, 2019 Filed Jun 14, 2019 12:08 UTC |
Arnost Thomas MDirector · Executive Chairman · 10% owner
|
GrantCommon Stock Warrants · Derivative | 625,000 | Not disclosed Strike: $0.12 | Not disclosed |
DisclosureSEC source: 0001683168-19-001893 · ownership.xml · derivative · entry 2 Arnost Thomas M · CIK 0001404737 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,833,335 Underlying: Common Stock · 625,000 shares Expires 2023-09-30 F1 · price: Not applicable Read SEC document |
| May 03, 2019 Filed Jun 14, 2019 12:08 UTC |
Arnost Thomas MDirector · Executive Chairman · 10% owner
|
SaleCommon Stock | 1,250,000 | $0.08 | $100,000.00 |
DisclosureSEC source: 0001683168-19-001893 · ownership.xml · nonDerivative · entry 1 Arnost Thomas M · CIK 0001404737 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,832,120 Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 21:20 UTC |
Salkind GeneDirector · 10% owner
|
GrantWarrants · Derivative | 6,250,000 | Not disclosed Strike: $0.12 | Not disclosed |
DisclosureSEC source: 0001683168-19-000951 · ownership.xml · derivative · entry 2 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,250,000 Underlying: Common Stock · 6,250,000 shares Expires 2023-09-30 F2 · price: Not applicable. Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 21:20 UTC |
Salkind GeneDirector · 10% owner
|
GrantCommon Stock | 12,500,000 | $0.08 | $1,000,000.00 |
DisclosureSEC source: 0001683168-19-000951 · ownership.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,783,355 F1 · balance_after: Excludes Preferred Stock Convertible into 150 Million Common Shares and Warrants to purchase an additional 150 million Common Shares. Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 21:20 UTC |
Iacovone AnthonyDirector
|
GrantConvertible Notes · Derivative | 312,500 | Not disclosed Strike: $0.12 | Not disclosed |
DisclosureSEC source: 0001683168-19-000950 · ownership.xml · derivative · entry 2 Iacovone Anthony · CIK 0001766713 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,562,500 Underlying: Common Stock · 312,500 shares Expires 2023-09-30 F1 · price: Not applicable. Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 21:20 UTC |
Iacovone AnthonyDirector
|
GrantCommon Stock | 625,000 | $0.08 | $50,000.00 |
DisclosureSEC source: 0001683168-19-000950 · ownership.xml · nonDerivative · entry 1 Iacovone Anthony · CIK 0001766713 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Corporation Disclosed balance after: 16,709,700 Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 11:58 UTC Amendment |
Iacovone AnthonyDirector
|
GrantWarrants · Derivative | 312,500 | Not disclosed Strike: $0.12 | Not disclosed |
DisclosureSEC source: 0001683168-19-000956 · ownership.xml · derivative · entry 2 Iacovone Anthony · CIK 0001766713 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,562,500 Underlying: Common Stock · 312,500 shares Expires 2023-09-30 F1 · price: Not applicable. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 11:58 UTC Amendment |
Iacovone AnthonyDirector
|
GrantCommon Stock | 625,000 | $0.08 | $50,000.00 |
DisclosureSEC source: 0001683168-19-000956 · ownership.xml · nonDerivative · entry 1 Iacovone Anthony · CIK 0001766713 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Corporation Disclosed balance after: 16,709,700 Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 21:21 UTC |
Trepeta SeanDirector · Pres of Mobiquity Networks
|
GrantCommon Stock Options · Derivative | 10,000,000 | Not disclosed Strike: $0.15 | Not disclosed |
DisclosureSEC source: 0001683168-19-000952 · ownership.xml · derivative · entry 1 Trepeta Sean · CIK 0001538450 · Director · Pres of Mobiquity Networks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,150,001 Underlying: Common Stock · 10,000,000 shares Expires 2029-04-02 F2 · security: Vesting of options is 35% immediately, 35% after one year and the balance after 2 years. F1 · price: Not applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 21:19 UTC |
Bauersfeld PaulChief Technology Officer
|
GrantCommon Stock Options · Derivative | 10,000,000 | Not disclosed Strike: $0.15 | Not disclosed |
DisclosureSEC source: 0001683168-19-000948 · ownership.xml · derivative · entry 1 Bauersfeld Paul · CIK 0001629264 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,150,000 Underlying: Common Stock · 10,000,000 shares Expires 2029-04-02 F2 · security: Vesting of options is 35% immediately, 35% after one year and the remaining 30% after two years. F1 · price: Not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.